Alembic Pharmaceuticals Ltd. share price target

Alembic Pharmaceuticals posted sales of Rs872cr (vs. Rs1,008cr in 2QFY2016), a dip of 13.5% yoy, mainly on back of base effect. International business declined owing to lower contribution from Abilify. On the operating front, the gross margin is expected to come in at 72.5% (vs. 77.5% in 2QFY2016) and EBIDTA margin at 20.3% (vs. 37.2% in ..

ALPMs top line declined 14% YoY, EBITDA margin came in at 20.4% (-1689bps YoY) and PAT stood at Rs 1.2bn (down 58%YoY) on a high base of 2QFY16 which included substantial gAbilify sales. However, sequential numbers made for better reading with ALPM effecting a revenue growth of 20% on the back of better season for acute products in India business and improved traction in the US base business.

ICICI Securities Ltd | Retail Equity Research Revenues declined 13% YoY to | 879 crore (I-direct estimate: | 817 crore) mainly on account of higher base of gAbilify in Q2FY16. Export sales declined 38% to | 352 crore, higher than I-direct estimate of | 313 crore. Domestic branded formulation sales grew 19% to | 338 crore (I-direct estimates: | 336 crore) on account of 22% growth in the acute portfolio and 16% growth in the speciality portfolio EBITDA margins were at 20.2% (I-direct estimate: 20.0%) vs. 37.3%...

Alembic pharmaceuticals Ltd. (APL) is the Indian pharmaceutical major head quartered in vadodara (Gujarat). The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates. APL is one of the old pharmaceutical companies in India, incorporated in 1907. The company has strong domestic presence in the formulation business. The company has...

For 1QFY2017, Alembic Pharmaceuticals posted sales of Rs727cr V/s Rs583cr in 1QFY2016, ie a yoy growth of 24.8%. Formulations (Rs607.6cr) grew 29.3% yoy, while API (Rs128cr) grew 7.0% yoy. On the operating profit front, the OPM came in at 21.4% V/s 17.4% in 1QFY2016 and V/s 22.7% expected. Expansion in the OPM was mainly on back of gross ..

Incremental revenues from the front-end in the US, and a sequential uptick in gAbilify sales led to 25% YoY revenue growth in 1QFY17. EBITDA at Rs 1.5bn was up 55% YoY and margins improved to 21.3% ( 423bps). Driven by strong operating performance, PAT grew 48% YoY to Rs 1bn.

ICICI Securities Ltd | Retail Equity Research Revenues grew 24.8% YoY to | 728 crore (I-direct estimate: | 647.5 crore) on account of continuous windfall gains from gAbilify sales in the US. Export sales grew 75.2% to | 308.5 crore (I-direct estimate: | 228.7 crore. Domestic branded formulation sales grew 5.7% to | 277.7 crore (I-direct estimate: | 275.8 crore) on the back of 16% growth in the speciality portfolio EBITDA margins improved 407 bps YoY to 21.6% (I-direct estimate:...

Alembic Pharma's (ALPM) 1Q results were broadly in line with our estimates. Sales grew 25% YoY to INR7.3b, ~3.5% above our estimate primarily due to strong growth in international business partially offset by muted growth in domestic business. EBITDA margin was 21.4% against our estimate of 20.7% due to lower than expected R&D; cost of 11% (our estimate was ~13%), partially offset by higher operating expense. International business shines; domestic business impacted by regulatory actions: International business grew >70% YoY and >60% QoQ due to increase...

Alembic Pharmaceuticals' 4QFY2016 results have come in below our expectations, on the sales front. The company posted sales of Rs626cr (V/s Rs763cr expected) for the quarter, registering a yoy growth of 24.7%. The growth in sales was driven by international formulations (Rs190.2cr) which grew 20% yoy, while Indian formulations (Rs259.6cr)..

ICICI Securities Ltd | Retail Equity Research Revenues grew 24.6% YoY to | 626.6 crore, lower than I-direct estimate of | 840.2 crore mainly due to lower-than-expected export...